Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.4M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
38.6M
-
Shares change
-
+16.7M
-
Total reported value, excl. options
-
$136M
-
Value change
-
+$59.2M
-
Put/Call ratio
-
0.27
-
Number of buys
-
39
-
Number of sells
-
-18
-
Price
-
$3.53
Significant Holders of Poseida Therapeutics, Inc. - Common Stock, par value $0.0001 per share (PSTX) as of Q3 2022
74 filings reported holding PSTX - Poseida Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2022.
Poseida Therapeutics, Inc. - Common Stock, par value $0.0001 per share (PSTX) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.6M shares
of 98.4M outstanding shares and own 39.2% of the company stock.
Largest 10 shareholders include FMR LLC (12.5M shares), Pentwater Capital Management LP (5.98M shares), EcoR1 Capital, LLC (2.65M shares), SILVERARC CAPITAL MANAGEMENT, LLC (2.55M shares), VANGUARD GROUP INC (2.38M shares), Paradigm Biocapital Advisors LP (2.07M shares), Cormorant Asset Management, LP (1.85M shares), WELLINGTON MANAGEMENT GROUP LLP (1.19M shares), Aisling Capital Management LP (1.04M shares), and PERCEPTIVE ADVISORS LLC (750K shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.